Stocks making the biggest moves premarket: CoreWeave, Rocket Lab Corp, SK Hynix & more

Premarket moves were mixed: CoreWeave fell 6% and SK Hynix slid more than 7% amid investor concerns about borrowing to fund AI build-outs, while Rocket Lab dropped nearly 10% after delaying Neutron's launch to 2027. Penske Automotive rose 8% after agreeing to a $212-per-share cash take-private deal, nearly a 9% premium to Wednesday's close, with closing expected in Q1 2027. Walmart gained more than 2% after Deutsche Bank upgraded it to buy, and Crocs rose nearly 2% after Barclays upgraded it to overweight.

Analysis

The market is pricing AI build-out funding risk, not just near-term demand. CRWV is the cleaner financing-sentiment proxy; SKHY also carries broad Korea-market beta, so its decline alone does not establish a deterioration in memory fundamentals. If hyperscaler capex plans and memory pricing remain intact, SKHY’s selloff could prove more reversible than CRWV’s. Conversely, weaker customer spending would pressure both infrastructure utilization expectations and memory demand. Track capex guidance, financing disclosures, and memory pricing over the next 1–3 months; a sustained capex pullback would extend the risk to suppliers and equipment names.

RKLB’s Neutron slip raises execution and schedule credibility risk, shifting investor focus toward evidence of milestones rather than distant addressable-market claims. The 2027 timing leaves a longer window for further delays; contract or test milestones are the key near-term checks.

PAG’s cash deal creates a defined-value event, but the quoted offer is not a guaranteed floor: closing is distant, and financing, approvals, and deal terms need verification. Without the post-jump price, the remaining spread cannot be assessed. WMT’s upgrade may support defensive retail positioning, but incremental-margin improvement and inflation-driven traffic are analyst theses, not confirmed outcomes. CROX’s upgrade is similarly dependent on product/category execution and international demand. Contrarian angle: the AI selloff may be overgeneralizing financing risk to memory exposure, while the Neutron delay may be underweighting how much execution evidence investors will require.

Key Decisions for Investors

• Avoid chasing CRWV weakness as a standalone short. For a cautious relative-value expression, consider a small CRWV-underweight versus WMT-overweight only if AI funding concerns persist; reassess on capex guidance and CRWV financing disclosures. Falsifier: stable or rising customer capex alongside improving infrastructure utilization evidence.
• Keep SKHY on a conditional watch rather than extrapolating the Kospi-led drop: consider adding only if memory pricing and customer demand indicators hold while the broad-market shock stabilizes. Falsifier: weakening pricing or evidence of customer capex cuts.
• Do not buy PAG solely for the announced premium. Check the current share price against the $212 cash consideration and verify financing, approvals, and termination provisions; avoid the deal-spread trade if the residual return does not compensate for the long closing timeline and break risk.
• Treat RKLB as a milestone-driven risk position: avoid adding ahead of verifiable Neutron progress, and reduce exposure if further schedule slippage occurs. Revisit on concrete test or development milestones rather than the revised date alone.
• WMT and CROX upgrades are not independently verified catalysts. Monitor WMT margin and traffic trends and CROX category/international execution before chasing the initial move; thesis fails if subsequent company commentary or results do not support those drivers.